BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33889952)

  • 1. Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia.
    Palandri F; Rossi E; Bartoletti D; Ferretti A; Ruggeri M; Lucchini E; Carrai V; Barcellini W; Patriarca A; Rivolti E; Consoli U; Cantoni S; Oliva EN; Chiurazzi F; Caocci G; Giuffrida G; Borchiellini A; Auteri G; Baldacci E; Carli G; Nicolosi D; Sutto E; Carpenedo M; Cavo M; Mazzucconi MG; Zaja F; De Stefano V; Rodeghiero F; Vianelli N
    Blood; 2021 Aug; 138(7):571-583. PubMed ID: 33889952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial Experience with the Use of Thrombopoetin Receptor Agonists in Patients with Refractory HIV-Associated Immune Thrombocytopenic Purpura: A Case Series.
    Kowalczyk M; Rubinstein PG; Aboulafia DM
    J Int Assoc Provid AIDS Care; 2015; 14(3):211-6. PubMed ID: 25504472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
    González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
    Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review.
    Depré F; Aboud N; Mayer B; Salama A
    Blood Transfus; 2018 May; 16(3):307-312. PubMed ID: 28151387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
    Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study.
    Michel M; Ruggeri M; Gonzalez-Lopez TJ; Alkindi S; Cheze S; Ghanima W; Tvedt THA; Ebbo M; Terriou L; Bussel JB; Godeau B
    Blood; 2020 Dec; 136(26):3056-3061. PubMed ID: 32814348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice.
    Iino M; Sakamoto Y; Sato T
    Int J Hematol; 2020 Aug; 112(2):159-168. PubMed ID: 32476083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia.
    Alvarez Román MT; Fernández Bello I; Arias-Salgado EG; Rivas Pollmar MI; Jiménez Yuste V; Martín Salces M; Butta NV
    Thromb Haemost; 2014 Jul; 112(1):65-72. PubMed ID: 24500066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists.
    Guitton Z; Terriou L; Lega JC; Nove-Josserand R; Hie M; Amoura Z; Bussel JB; Hamidou M; Rosenthal E; Lioger B; Chauveau D; Chaminade A; Magy-Bertrand N; Michel M; Audia S; Godeau B; Mahevas M
    Rheumatology (Oxford); 2018 Aug; 57(8):1432-1438. PubMed ID: 29757439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists.
    Ghadaki B; Nazi I; Kelton JG; Arnold DM
    Transfusion; 2013 Nov; 53(11):2807-12. PubMed ID: 23451917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant.
    Bento L; Bastida JM; García-Cadenas I; García-Torres E; Rivera D; Bosch-Vilaseca A; De Miguel C; Martínez-Muñoz ME; Fernández-Avilés F; Roldán E; Chinea A; Yáñez L; Zudaire T; Vaz CP; Espigado I; López J; Valcárcel D; Duarte R; Cabrera R; Herrera C; González-Porras JR; Gutiérrez A; Solano C; Sampol A;
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1825-1831. PubMed ID: 31152794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series.
    Poston JN; Gernsheimer TB
    Int J Hematol; 2019 Aug; 110(2):255-259. PubMed ID: 30972617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center.
    Suntsova EV; Maschan AA; Baydildina DD; Kalinina II; Petrova UN; Pshonkin AV; Novichkova GA
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27704. PubMed ID: 30854783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia.
    Khellaf M; Viallard JF; Hamidou M; Cheze S; Roudot-Thoraval F; Lefrere F; Fain O; Audia S; Abgrall JF; Michot JM; Dauriac C; Lefort S; Gyan E; Niault M; Durand JM; Languille L; Boutboul D; Bierling P; Michel M; Godeau B
    Haematologica; 2013 Jun; 98(6):881-7. PubMed ID: 23445876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
    Zhang J; Liang Y; Ai Y; Xie J; Li Y; Zheng W
    Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment patterns in adults with immune thrombocytopenia before, during and after use of thrombopoietin receptor agonists: a longitudinal prescription database study from Germany.
    Meyer O; Richter H; Lebioda A; Schill M
    Hematology; 2021 Dec; 26(1):697-708. PubMed ID: 34547980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia.
    Neunert CE
    Hamostaseologie; 2019 Aug; 39(3):272-278. PubMed ID: 30646404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
    Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
    Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.